Leerink Partners analyst, Michael Schmidt, recapped the Alnylam Pharmaceuticals (NASDAQ: ALNY) pipeline update from 1Q results and cut his price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE